PAVM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PAVmed Inc is not a strong buy at this time for a beginner investor with a long-term focus. The technical indicators are bearish, there are no significant positive trading signals, and the financial performance shows mixed results with significant losses. While the stock has seen a substantial revenue increase, the net income and gross margin are deeply negative, indicating financial instability. Additionally, there are no recent positive catalysts or strong analyst support to justify an immediate buy.
The technical indicators are bearish. The MACD is negatively expanding below zero, RSI is neutral at 36.499, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 9.15, with resistance levels at 9.99 and 10.25.
Revenue increased by 420.00% YoY in Q4 2025, and EPS improved by 469.44% YoY.
Net income dropped significantly to -$1,832,000 (-236.11% YoY), and gross margin fell to -63.46% (-83.30% YoY). Analysts have lowered the price target from $60 to $16, citing equity dilution concerns. No recent news or significant trading trends from hedge funds, insiders, or congress.
In Q4 2025, revenue increased to $52,000 (up 420.00% YoY), but net income dropped to -$1,832,000 (-236.11% YoY). EPS improved to -2.05 (up 469.44% YoY), but gross margin fell sharply to -63.46% (-83.30% YoY), indicating poor profitability.
Maxim recently lowered the price target from $60 to $16, maintaining a Buy rating but highlighting concerns about equity dilution and a higher share count.
